Telmisartan vs. Perindopril in Mild-Moderate Alzheimer’s Disease Patients (SARTAN-AD) trial

What is the study about?

The SARTAN-AD study is comparing the effects of two approved medications for high blood pressure – Telmisartan and Perindopril – on their ability to maintain brain function in people with mild to moderate Alzheimer’s disease.

 

Eligibility–Who can participate?

Participants must:

• Be 50 years of age or older
• Have a diagnosis of Alzheimer’s disease
• Have had a previous MRI or CT brain scan
• Have a study partner who can come to all study visits

Time requirement:

• Screening visit
  • In-person—3 hours
  • Phone/Email – 10 min
  • In-Person MRI -1 hour

• Baseline visit (in person)—4 hours
• Week 2 follow-up (phone or in person)—15-30 mins
• Month 1 follow-up (in person)—1 hour
• Month 3 follow-up (phone or in person)—1 hour
• Month 6 follow-up (in person)—4 hours
• Month 9 follow-up (phone or in person)—1 hour
• Month 12 follow-up (in person)—5 hours

TDRA investigator

Drs. Sandra Black and Sanjeev Kumar

 

More information

https://clinicaltrials.gov/ct2/show/NCT02085265

TDRA Site:

Centre for Addiction and Mental Health (CAMH)

Address: 1001 Queen St W, Toronto, ON M6J 1H4

Sunnybrook Health Sciences Centre

Address: 2075 Bayview Ave, Toronto, ON M4N 3M5

Age Group:

50 - 54, 55 - 59, 60 - 64, 65 - 69, 70 - 80, 81 - 85, 86 - 90, 91+

Target Population:

Alzheimer’s disease